Larson Financial Group’s Inovio Pharmaceuticals INO Stock Holding History

Larson Financial Group’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8	Closed	-$16	–	3547
2025 Q2	$16	Hold	8	–	–	﹤0.01%	3257
2025 Q1	$13	Sell	8 -83	-91%	-$167	﹤0.01%	3049
2024 Q4	$167	Hold	91	–	–	﹤0.01%	2492
2024 Q3	$526	Buy	91 +83	+1,038%	+$685	﹤0.01%	2115
2024 Q2	$65	Hold	8	–	–	﹤0.01%	2325
2024 Q1	$111	Hold	8	–	–	﹤0.01%	1692
2023 Q4	$51	Hold	8	–	–	﹤0.01%	1757
2023 Q3	$39	Hold	8	–	–	﹤0.01%	1683
2023 Q2	$45	Hold	8	–	–	﹤0.01%	1544
2023 Q1	$82	Hold	8	–	–	﹤0.01%	1506
2022 Q4	$156	Hold	8	–	–	﹤0.01%	1438
2022 Q3	$0	Hold	8	–	–	﹤0.01%	1342
2022 Q2	$0	Hold	8	–	–	﹤0.01%	1239
2022 Q1	$0	Hold	8	–	–	﹤0.01%	1105
2021 Q4	$0	Buy	+8	New	+$641	﹤0.01%	1121
2020 Q2	–	Sell	-6	Closed	-$1K	–	716
2020 Q1	$1K	Buy	+6	New	+$370	﹤0.01%	486

Other funds holding INO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Larson Financial Group's INO Position: Q3 2025 in Review

Larson Financial Group sold out of Inovio Pharmaceuticals (INO) in Q3 2025, closing a stake of 8 shares — an estimated $16 sold.

Larson Financial Group first reported a position in INO in Q1 2020 and held it in 16 quarters. The position peaked at $1K in Q1 2020. 99 funds tracked by Wall St. Rank hold INO as of Q3 2025.

Larson Financial Group reported no remaining Inovio Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Larson Financial Group sold 8 Inovio Pharmaceuticals shares in Q3 2025, an estimated $16.
Larson Financial Group first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 16 quarters.
Larson Financial Group's Inovio Pharmaceuticals position peaked at $1K in Q1 2020.
99 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2025.

Based on Larson Financial Group's 13F filing for Q3 2025, filed 14 Nov 2025.